toluene-4-sulfonic acid (2R)-6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester | 943250-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: toluene-4-sulfonic acid (2R)-6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester
• 英文别名: toluene-4-sulfonic acid (2S)-6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester
• CAS: 943250-85-9
• 化学式: C₁₆H₁₄Cl₂O₅S
• 分子量: 389.256
• InChiKey: RJAJUWDTUUWGJE-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.85
• 重原子数：
  24.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.83
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  toluene-4-sulfonic acid (2R)-6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以80%的产率得到(2S)-2-(6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-isoindole-1,3-dione
  参考文献：
  名称：

  USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER

  摘要：

  本发明涉及一种治疗躁狂症和/或双相情感障碍的方法，包括向需要的受试者施用根据本文所定义的一个或多个新型苯并杂环磺酰胺衍生物的治疗有效量，其化学式分别为(I)和(II)。

  公开号：

  US20070155826A1
• 作为产物：
  描述：

  2S-(6,7-dichloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methanol 、 对甲苯磺酰氯 在 吡啶 作用下， 反应 20.0h， 生成 toluene-4-sulfonic acid (2R)-6,7-dichloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester
  参考文献：
  名称：

  USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER

  摘要：

  本发明涉及一种治疗躁狂症和/或双相情感障碍的方法，包括向需要的受试者施用根据本文所定义的一个或多个新型苯并杂环磺酰胺衍生物的治疗有效量，其化学式分别为(I)和(II)。

  公开号：

  US20070155826A1

文献信息

• USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070155823A1

  公开（公告）日：2007-07-05

  The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and/or for preventing neuron death or damage following brain, head and/or spinal cord trauma or injury comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined.

  本发明是一种神经保护方法，用于治疗急性神经退行性疾病，治疗慢性神经退行性疾病和/或预防脑部、头部和/或脊髓创伤或损伤后的神经元死亡或损伤，包括向需要的受试者施用本文定义的一种或多种新型苯并杂环磺酰胺衍生物的治疗有效量，其化学式为(I)和化学式(II)。
• USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070155825A1

  公开（公告）日：2007-07-05

  The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and/or formula (II) as herein defined.

  本发明涉及一种用于治疗酒精滥用和/或成瘾的方法，包括向需要的受试者施用一种或多种新型苯并杂环磺酰胺衍生物的治疗有效剂量，其化学式如下所定义：（I）和/或（II）。
• WO2007/75833
  申请人：——

  公开号：——

  公开（公告）日：——
• Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Pharmacological Properties of (<i>S</i>)-<i>N</i>-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112)
  作者：David F. McComsey、Virginia L. Smith-Swintosky、Michael H. Parker、Douglas E. Brenneman、Ewa Malatynska、H. Steve White、Brian D. Klein、Karen S. Wilcox、Michael E. Milewski、Mark Herb、Michael F. A. Finley、Yi Liu、Mary Lou Lubin、Ning Qin、Allen B. Reitz、Bruce E. Maryanoff

  DOI：10.1021/jm400894u

  日期：2013.11.27

  Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.